- 4 National Health Commission of the People's Republic of China. Notice of the General Office of the National Health and Health Commission on issuing a new coronavirus pneumonia prevention and control plan (4th edition). http://www.nhc.gov.cn/xcs/zhengcwj/202002/573340613a b243b3a7f61df260551dd4.shtml (accessed Feb 7, 2020).
- 5 Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; published online Feb 12. https://doi.org/10.1016/S0140-6736(20)30360-3.
- 6 Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; published online Jan 30. https://doi.org/10.1016/ S0140-6736(20)30251-8.
- 7 Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631–37.
- 8 To KF, Lo AW. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 2004; 203: 740-43.
- 9 Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191: 792-97

- 10 National Health Commission of the People's Republic of China. Transcript of Press Conference on Feb 7, 2020. http://www.nhc.gov.cn/xcs/s3574/20200 2/5bc099fc9144445297e8776838e57ddc.shtml (accessed Feb 7, 2020; in Chinese)
- 11 Lam CM, Wong SF, Leung TN, et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. BJOG 2004; 111: 771–74.
- 12 Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr* 2020; published online Feb 10. DOI:10.21037/tp.2020.02.06.
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; published online Jan 30. https://doi.org/ 10.1016/S0140-6736(20)30211-7.
- 14 Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020.
- National Health Commission of the People's Republic of China. Notice on strengthening maternal disease treatment and safe midwifery during the prevention and control of new coronavirus pneumonia. http://www.nhc. gov.cn/xcs/zhengcwj/202002/4f80657b346e4d6ba76e2cfc3888c630. shtml (accessed Feb 8, 2020).



Scientists are sprinting to outpace the novel coronavirus

Published Online February 20, 2020 https://doi.org/10.1016/ 50140-6736(20)30420-7 For the Arabic translation see Online for appendix 1 For the Chinese translation see Online for appendix 2 For the French translation see Online for appendix 3 For the Russian translation see Online for appendix 4 For the Spanish translation see Online for appendix 4 The number of people with novel coronavirus disease 2019 (COVID-19) has risen above 75 000 globally, over 99% of whom are in China, with more than 900 cases in 25 other countries as of Feb 20, 2020.^{1,2} Science, however, is stepping up to the challenge. Consider the example of Africa's efforts to scale up its capacity to detect any cases of infection.

On Feb 3, 2020, the only African countries with laboratories that could test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were South Africa and Senegal. This scarce capacity was a major concern for a continent bracing for possible infections. Just a fortnight later, WHO had sent testing kits to

27 countries on the continent, which are already being used.³ By the end of this week, the number of countries able to detect COVID-19 is expected to have risen to 40. The Africa Centres for Disease Control and Prevention has led training for these countries in Senegal, with further sessions scheduled for the week of Feb 24, 2020, in South Africa.³

The importance of the ability to test for SARS-CoV-2 in poorer countries cannot be overstated. It gives them the best chance of containment before the virus can spread and devastate weak health systems. Reliable diagnostics are crucial in the response to the outbreak.

Fortunately, scientists around the world are working at breakneck speed to figure out how to detect, treat, and control the new coronavirus. On Feb 10–12, 2020, WHO brought almost 400 scientists together for a research and innovation forum on the new coronavirus. The meeting covered the topics of diagnostics, vaccines, and therapeutics for COVID-19, alongside questions of how to best integrate social science into the response and protection of health-care workers from infection. The forum generated a research roadmap, due to be published at the end of February, 2020, to develop tools to help control the outbreak, reduce deaths, and minimise damage to economies and the social fabric of communities.

The roadmap is intended to enable scientists, researchers, and funders to coordinate and align



their efforts to address priorities. This roadmap aims to accelerate the development of new methods to fight the virus, including a diagnostic test that can be used in primary health care settings, even in the most vulnerable settings.

But even more encouraging was the energy and commitment of participants, who showed their solidarity and collaboration to help protect the world's health.

Urgent priorities and workplans were identified by the scientists. These included understanding human transmission of SARS-CoV-2; the role of personal protective equipment, such as masks, gloves, and aprons; optimising clinical management; preventive interventions to protect health workers treating patients with the disease; and studying the effects of restrictions on movement, such as with mass quarantines.

The forum also addressed important social and behavioural questions, including effective ways to address fear, rumours, and stigma; optimal strategies to promote adherence to public health measures; how to involve communities in the design, delivery, and dissemination of clinical research findings; and how to work with the media on public health messaging.

Scientists urged WHO to have a coordinating role, especially in ensuring equitable access to new therapies, diagnostics, and vaccines under development to all populations that need them.

China kickstarted the efforts that led to this meeting. Health authorities there have been working tirelessly to respond to and control the COVID-19 outbreak within China, providing countries around the world precious time needed to prepare for the possible arrival of the virus inside their borders. Importantly, health authorities in China have paved the way for the international scientific community to join the fight.

China's doctors laid the foundation for this mobilisation of scientific and research muscle by rapidly identifying the new coronavirus in the middle of the influenza season. Chinese scientists lifted obstacles to researching the virus by sharing its genome sequencing publicly.

The fact that this information was shared with networks worldwide is accelerating the design of vaccines and drugs targeted at the new coronavirus. Created in response to the shortcomings, including the pace of development of a vaccine, of the response to the west African Ebola epidemic, the Coalition for Epidemic Preparedness Innovation (CEPI) is now at the forefront

of efforts to develop a vaccine, aiming to bring one to clinical trial within 16 weeks.

2 months ago, COVID-19 was entirely unknown. Yet researchers have already managed to conduct studies on it. For example, we have found that the proportion of severe cases increases with age. Just as people originally caught severe acute respiratory syndrome coronavirus (SARS-CoV) from civets and Middle East respiratory syndrome coronavirus (MERS-CoV) from camels,⁵ we know that SARS-CoV-2 came from an animal. Researchers have also found that approximately 81% of known infections can be classified as mild and that 2.3% result in death.⁶

Every day we find out something new, through pursuing avenues of research such as viral shedding studies to see whether the new coronavirus is primarily transmitted by people with asymptomatic or more severe COVID-19. We are also looking to repeat the successes and avoid the mistakes from responses to Ebola, SARS, and avian influenza.⁷

Being better prepared is especially important in poorer countries, where resource-intensive interventions are unfortunately not an option. For example, determining the duration of the incubation period between infection and the presentation of symptoms will help ensure people are not kept in quarantine any longer than necessary, keeping costs down and reuniting families faster.

Even with all they have achieved so far, scientists need to continue their hard work. At the moment, we are shadow-boxing without the effective treatments or vaccines needed to hit this international public health emergency hard. In addition to convening the best minds from the worlds of science and public health, WHO is going to the heart of the outbreak. After our meetings with China's President Xi Jinping in Beijing, WHO agreed with the Chinese Government that a mission of experts in epidemiology, laboratories, research, and development would visit the country to improve understanding of the outbreak to quide global response efforts.

Through collaborating with partners from governments, the private sector, and the scientific community, we will continue to convene members of the global community to find shared answers to shared problems. WHO will work to pass this test of scientific solidarity and end the new coronavirus outbreak.

TAG is the Director-General of WHO. SS is Chief Scientist at WHO. We declare no other competing interests.

 $@\ 2020.\ World\ Health\ Organization.\ Published\ by\ Elsevier\ Ltd.\ All\ rights\ reserved.$

For more on sharing 2019 novel coronavirus genome sequencing publicly see https://www.gisaid.org/

For the Coalition for Epidemic Preparedness Innovation see https://cepi.net/

*Tedros Adhanom Ghebreyesus, Soumya Swaminathan DGOffice@who.int

World Health Organization, 1211 Geneva, Switzerland

- WHO. Coronavirus disease (COVID-2019) situation reports. Feb 19, 2020. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200218-sitrep-29-covid-19.pdf?sfvrsn=6262de9e_2 (accessed Feb 19, 2020)
- WHO. WHO Director-General's opening remarks at the mission briefing on COVID-19. Feb 19, 2020. https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-the-mission-briefing-on-covid-19 (accessed Feb 19, 2020).
- WHO. National capacities review tool for a novel coronavirus (nCoV), 2020. https://www.who.int/publications-detail/national-capacities-review-toolfor-a-novel-coronavirus-(ncov) (accessed Feb 19, 2020).
- WHO. World experts and funders set priorities for COVID-19 research. Feb 12, 2020. https://www.who.int/news-room/detail/12-02-2020-worldexperts-and-funders-set-priorities-for-covid-19-research (accessed

- WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). March 11, 2019. https://www.who.int/en/news-room/fact-sheets/detail/ middle-east-respiratory-syndrome-coronavirus-(mers-cov) (accessed
- The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)—China, 2020. China CDC Weekly 2020. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51 (accessed Feb 19, 2020).
- Global Preparedness Monitoring Board. Flagship report. 2019. https://apps. who.int/gpmb/flagship_report.html (accessed Feb 19, 2020).
- WHO. WHO, China leaders discuss next steps in battle against coronavirus outbreak. Jan 28, 2020. https://www.who.int/news-room/detail/28-01-2020-who-china-leaders-discuss-next-steps-in-battle-against-coronavirusoutbreak (accessed Feb 19, 2020).



(IV) COVID-19 control in China during mass population movements at New Year

Published Online February 20, 2020 https://doi.org/10.1016/ 50140-6736(20)30421-9 For the Chinese translation see Online for appendix

The outbreak of novel coronavirus disease 2019 (COVID-19) continues to spread rapidly in China.1 The Chinese Lunar New Year holiday, the start of which coincided with the emergence of COVID-19, is the most celebratory time of the year in China, during which a massive human migration takes place as individuals travel back to their hometowns. People in China are estimated to make close to 3 billion trips over the 40-day travel period, or Chunyun, of the Lunar New Year holiday.² About 5 million people left Wuhan,3 the capital city of Hubei province and epicentre of the COVID-19 epidemic, before the start of the travel ban on Jan 23, 2020. About a third of those individuals travelled to locations outside of Hubei province.4 Limiting the social contacts of these individuals was crucial for COVID-19 control, because patients with no or mild symptoms can spread the virus.⁵

Government policies enacted during the Chinese Lunar New Year holiday are likely to have helped reduce the spread of the virus by decreasing contact and increasing physical distance between those who have COVID-19 and those who do not. As part of these social distancing policies, the Chinese Government encouraged people to stay at home; discouraged mass gatherings; cancelled or postponed large public events; and closed schools, universities, government offices, libraries, museums, and factories. 6-10 Only limited segments of urban public transport systems remained operational and all cross-province bus routes were taken out of service. As a result of these policies and public information and education campaigns, Chinese citizens started to take measures to protect themselves against COVID-19, such as staying at home as far as possible, limiting social contacts, and wearing protective masks when they needed to move in public.

Social distancing has been effective in past disease epidemics, curbing human-to-human transmission and reducing morbidity and mortality.11-17 A single social distancing policy can cut epidemic spread, but usually multiple such policies-including more restrictive measures such as isolation and quarantine—are implemented in combination to boost effectiveness. For example, during the 1918-19 influenza pandemic, the New

